E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
High risk haematological malignancies |
|
E.1.1.1 | Medical condition in easily understood language |
cancer affecting blood, bone marrow, lymph nodes |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000845 |
E.1.2 | Term | Acute lymphoblastic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000886 |
E.1.2 | Term | Acute myeloid leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009015 |
E.1.2 | Term | Chronic myeloid leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028534 |
E.1.2 | Term | Myelodysplastic syndrome NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006597 |
E.1.2 | Term | Burkitt's lymphoma NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10076434 |
E.1.2 | Term | Hepatosplenic gamma-delta T-cell lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025315 |
E.1.2 | Term | Lymphoma malignant |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036889 |
E.1.2 | Term | Prolymphocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10073481 |
E.1.2 | Term | Enteropathy-associated T-cell lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054481 |
E.1.2 | Term | Natural killer-cell leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054655 |
E.1.2 | Term | T-cell type acute leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000836 |
E.1.2 | Term | Acute leukemia NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067837 |
E.1.2 | Term | Acute biphenotypic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054681 |
E.1.2 | Term | Undifferentiated type acute leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall study objective is to compare the safety and efficacy of NiCord single ex-vivo expanded cord blood unit transplantation to unmanipulated cord blood unit transplantation in patients with hematological malignancies following conditioning therapy |
|
E.2.2 | Secondary objectives of the trial |
Not applicable - see primary and secondary endpoints sections |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.12-65 years of age 2.Patients with one of the following HM: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), CMMoL or MDS/CMMoL overlap, Myelodysplastic Syndrome (MDS) and Lymphoma as defined in the protocol. Biphenotypic/undifferentiated/Prolymphocytic/Dendritic Cell Leukemias and Natural Killer Cell Malignancies in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR. Patients with CLL are not eligible regardless of disease status. 3.CBU criteria as described in the protocol; 4.Patients who will be starting conditioning prior to NiCord release for infusion (i.e., NiCord arrival on site in adequate condition) must have an additional partially HLA-matched CBU reserved as a BU to the NiCord arm in case of production failure. The BU CBU must be HLA-matched at 4-6/6 HLA class I(HLA-A&HLA-B, low resolution) and II (HLA-DRB1,high resolution) loci with the patient. A second BU CBU is recommended to be added in the below cases: If the BU CBU is HLA matched at 5-or 6/6, and contains a pre-cryopreserved total nucleated cell dose of<2.5x10^7 TNC/kg, OR a pre-cryopreserved CD34+ cell dose of<1.2 x10^5CD34+ cells/kg. If the BU CBU is HLA-matched at 4/6, and contains a pre-cryopreserved total nucleated cell dose of<3.5x10^7 TNC/kg, OR a pre cryopreserved CD34+ cell dose of <1.7x10^5CD34+cells/kg. In case of two BU CBUs, the second BU CBU must also be HLA-matched at 4-6/6 HLA class I(HLA-A&HLA-B, low resolution) and II (HLA-DRB1,high resolution) loci with the patient. The BU CBUs are recommended to have a combined pre-cryopreserved total nucleated cell dose of at least 3x10^7 TNC/kg. 5.Patient's Performance score ≥70% by Karnofsky or Lansky 6. Patient has sufficient physiologic reserves including: a.Cardiac: LVEF of ≥40% by echocardiogram, radionuclide scan or cardiac MRI, or Left ventricular shortening fraction ≥ 29%. b.PFT demonstrating FVC and FEV1 of >50% of predicted for age and cDLCO>50% of predicted for patients in whom pulmonary function testing can be performed c.Renal: Creatinine clearance test ≥60mL/min d.Hepatic: Serum Bilirubin<2.0 mg/dl; Hepatic transaminases<3xupper limit of normal range 7.Females of childbearing potential, defined as any female who has experienced menarche and is not postmenopausal or permanently sterilized, agree to use an appropriate method of contraception from at least 7 days prior to conditioning regimen therapy until completion of FU procedures. 8.Patient signs the written informed consent after being aware of the nature of the patient's disease and willingly consents to the treatment program after being informed of alternative treatments, potential risks, benefits, and discomforts |
|
E.4 | Principal exclusion criteria |
1.MDS or CML with "marked" or "3+" fibrosis 2. CLL 3.Fewer than 21 days have elapsed since initiation of the patient's last chemotherapy cycle and the initiation of the stem cell transplant preparative regimen (radiotherapy,intrathecal agents, hydroxyurea, tyrosine kinase inhibitors, hypomethylating agents, rituximab, blinatumomab and lenalidomide are not considered chemotherapy) 4.Persistent clinically significant toxicities that, in the investigator's opinion, make the patient unsuitable for transplant 5.Evidence of donor specific anti-HLA antibodies to the selected treatment CBU #1 (MFI>3000 to HLA A, B, C, or DRB1) 6.Evidence of HIV infection or HIV positive serology 7.Evidence of active Hepatitis B or Hepatitis C as determined by serology or PCR 8.Pregnancy, as indicated by a positive serum or urine human chorionic gonadotrophin (HCG) test, or lactation 9.Active malignancy other than that for which the UCB transplant is being performed within 12 months of enrollment. Fully resected cutaneous squamous cell or basal cell carcinoma or cervical carcinoma in situ within 12 months of enrollment will be permitted. 10.Evidence of uncontrolled bacterial, fungal or viral infections or severe concomitant diseases, which in the judgment of the Principal investigator indicate that the patient could not tolerate transplantation 11.Patients with presence of leukemic blasts in the central nervous system (CNS) 12.Patients with an 8/8 allele level HLA-matched and readily available related or unrelated donor (whose stem cells can be collected in a timely manner without jeopardizing recipient outcome). Patients who have haploidentical related donors or syngeneic will not be excluded 13.Prior allogeneic hematopoietic stem cell transplant 14.Allergy to bovine products, gentamicin, or to any other product that may interfere with the treatment 15.Psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance and/or psychiatric illness and/or social situations that would limit compliance with study requirements 16.Enrolled in another interventional clinical trial or received an investigational treatment within 30 days prior to the approved date of randomization, unless documented approval obtained from Sponsor prior to the anticipated date of randomization, unless documented approval obtained from Sponsor prior to randomization |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Assess the time to neutrophil engraftment following transplantation. Neutrophil engraftment is defined as achieving an absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L on 3 consecutive measurements on different days with subsequent donor chimerism (≤10% host cells by peripheral blood chimerism or bone marrow chimerism if peripheral blood chimerism is not available). The day of neutrophil engraftment is designated as the first of the 3 consecutive measurements and must occur on or before 42 days post transplant (and also prior to infusion of any additional stem cell product). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints: •Incidence of grade 2/3 bacterial or invasive fungal infections by 100 days following transplantation •Days alive and out of hospital in the first 100 days following transplantation •Platelet engraftment by 42 days following transplantation Tertiary Endpoint: •Non-relapse mortality by 210 days following randomization Exploratory Endpoints: •Neutrophil engraftment by 16 days following transplantation •Time from transplantation to platelet engraftment •Duration of primary hospitalization •Non-relapse mortality by 130 days and 15 months following randomization •Overall survival at 210 days and 15 months following randomization •Disease-free survival at 15 months following randomization •Neutrophil engraftment by 42 days following transplantation •Acute GvHD grade II-IV and III-IV by 100 days following transplantation •Chronic GvHD (mild/moderate/severe) by 180 days and 1 year following transplantation •Secondary graft failure by 1 year following transplantation •Grade 3 viral infections by 180 days and 1 year following transplantation •Safety and tolerability of NiCord® transplantation •Relapse by 15 months following randomization •Relapse mortality by 15 months following randomization •Immune reconstitution at 28, 70, 100, 180, and 365 days following transplantation • Supplemental immune reconstitution assessments at a central laboratory (optional) •Health-related quality of life • Long-term clinical outcomes up to 5 years following transplantation (optional) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary Endpt: d 100 following transplant d 100 following transplant d 42 following transplant Tertiary Endpt: day 210 following randomization Exploratory Endpoints: day 16 following transplant NR NR d 130 and 15 m following randomization d 210 & 15 m following randomization 15 m following randomization d 42 following transplant d 100 following transplant d 180 & 1 yr following transplant 1 yr following transplantation d 180 & 1 yr following transplant NR 15 m following randomization 15 m following randomization day 28, 70, 100, 180 and 365 following transplantation MultiPlex analyses (d 7, 14, 21, 28, 42, 56, 70, 100, 180, & day 365 visits) & T cell receptor analysis (at screening and on days 100, 180 and 365 visits) NR 2 , 3, 4 & 5 yrs post transplantation
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
one or two Unmanipulated Umbilical Cord Blood Unit(s) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Israel |
Italy |
Netherlands |
Portugal |
Singapore |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |